The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Open accessAbstract
Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide (I/T) has activity in these patients, and the toxicity profile of I/T makes it an excellent backbone for study of new agents. Temsirolimus (TEM) and dinutuximab (DIN) were selected for testing with I/T in subjects with relapsed or refractory neuroblastoma. Methods Children’s Oncology Group (COG) ANBL1221, a randomised Phase II selection design trial, compared response and toxicity in subjects treated with I/T and either temsirolimus (I/T/TEM) or dinutuximab with granulocyte-macrophage colony stimulating factor (I/T/DIN). Patients were eligible at first relapse/progression or first designation of refractory disease, provided organ function requirements were met. Patients had to have histologic verification of neuroblastoma and/or demonstration of tumour cells in bone marrow with increased urinary catecholamines at diagnosis. Patients were eligible at first designation of relapse (defined as recurrence after response to treatment), or first designation of refractory disease (defined as inadequate response to treatment that included at least 4 cycles of ≥2 chemotherapeutic agents, including an alkylator and a platinum-containing compound. Patients previously treated for refractory or relapsed disease were ineligible. Computer-based randomisation with sequence generation defined by permuted block randomisation, with blocks of size 2, was used to assign patients 1:1 to I/T/TEM or I/T/DIN. Randomisation was stratified to ensure equal distribution of disease category (measurable vs. evaluable), prior exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status. Patients on both regimens received oral temozolomide (100 mg/m2/dose) and intravenous (IV) irinotecan (50 mg/m2/dose) on days 1–5 of 21-day cycles. TEM (35 mg/m2/dose IV) was given on days 1 and 8. DIN (17·5 or 25 mg/m2/day IV) was administered on days 2–5. The primary endpoint was objective (complete or partial) response; responses were centrally reviewed by an independent panel of radiologists. Response was analysed on an intent-to-treat basis. Toxicity was assessed in all participants who received at least one dose of protocol therapy. Follow up of the initial cohort is ongoing. This study is registered at ClinicalTrials.gov (NCT01767194). Findings Thirty-five eligible subjects were enrolled from February 22, 2013-March 23, 2015. Median age was 5.7 years (range 2·1–16·2 years; interquartile range (IQR) 4·5–9·1 years). Among 18 subjects randomised to I/T/TEM, 1 PR was observed (5·6%, 95% confidence interval (CI): [0·0%, 16·1%]). Among 17 patients randomised to I/T/DIN, 9 (53%, 95% CI: [29·2%, 76·7%]) had objective responses (4 PR, 5 CR), including responses in 5/10 patients with relapsed/progressive disease and 4/7 with refractory disease. I/T/DIN met protocol-defined criteria for selection as the combination meriting further study. The most common ≥Grade 3 toxicities among I/T/TEM patients were neutropenia (8/18; 44%), anemia (6/18; 33%), thrombocytopenia (5/18; 28%), increased alanine aminotransferase (5/18; 28%), and hypokalemia (4/18; 22%). The most common ≥Grade 3 toxicities among I/T/DIN patients were pain (7/17; 44%), hypokalemia (6/17; 38%), neutropenia (4/17; 25%), thrombocytopenia (4/17; 25%), anemia (4/17; 25%), fever/infection (4/17; 25%), and hypoxia (4/17; 25%). One I/T/DIN patient experienced Grade 3 peripheral motor neuropathy. Deaths during protocol therapy included an I/T/DIN patient who had PD in the chest and died of respiratory failure during Cycle 2 and an I/T/DIN patient who achieved CR after cycle 6 and died unexpectedly after 14 cycles of treatment. One I/T/DIN patient developed Grade 4 hypoxia possibly related to therapy and met protocol-defined criteria for unacceptable toxicity. Interpretation I/T/DIN shows significant anti-tumour activity in patients with relapsed or refractory neuroblastoma. Further evaluation of biomarkers in a larger cohort of patients may identify those most likely to respond to this chemo-immunotherapeutic regimen. Funding USA National Cancer Institute (NCI)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Cited by
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Davis, K. L., Fox, E., Merchant, M. S., Reid, J. M., Kudgus, R. A., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30023-1 · Cited by 337
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Nazha, B., Inal, C., & Owonikoko, T. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01000 · Cited by 324
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Tolbert, V. P., & Matthay, K. K. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2821-2 · Cited by 304
Metadata
- Authors
- Mody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., Bender, J. G., Maris, J. M., Park, J. R., & Bagatell, R.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 18
- Issue
- 7
- Pages
- 946-957
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2618869560
- Cited by
- 277
- References
- 58
- FWCI
- 16.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(17)30355-8
- The paper
- Mody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., Bender, J. G., Maris, J. M., Park, J. R., & Bagatell, R. (2017). Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(17)30355-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.